The company will report earnings before the open on Jan. 29
Israel-based pharmaceutical giant Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is preparing for its latest quarterly earnings report, due out before the open Wednesday, Jan. 29. The stock snapped its positive post-earnings streak in November with a 7.1% loss, marking its first negative earnings reaction in six quarters. This time around, analysts expect the company to post earnings of 70 cents per share, and a 7.3% decrease in revenue from a year ago, per Reuters.
On the charts, TEVA is still above its December bull gap levels, and isn't too far removed from its Dec. 27 six-year high of $22.88. Newfound support at the $21.50 region appears to be capturing today's pullback, with the stock down 1.4% at $21.47 at last glance. Year over year, the equity is up 81.5%.
When considering tomorrow's earnings volatility, it's worth noting that analysts are mostly bullish on Teva Pharmaceuticals stock. Of the eight brokerages in coverage, seven carry a "strong buy" rating, and one a "hold."